Cardiovascular catecholamine receptors in children: Their significance in cardiac disease

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 1, 2011, Pages 9-19

  Buijs, Erik A B ^a   Danser, Alexander H J ^b   Meijer, Natasja I F ^a   Tibboel, Dick ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

cardiac disease; cardiovascular; catecholamine receptor; human; pediatrics; young animal models

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; AMRINONE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CATECHOLAMINE RECEPTOR; DOBUTAMINE; DOPAMINE; ENOXIMONE; FENOLDOPAM; GLYCERYL TRINITRATE; NORADRENALIN; PHENOXYBENZAMINE; PROPRANOLOL;

AGE; CARDIOVASCULAR SYSTEM; CHILD; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; DRUG MEGADOSE; DUCTUS ARTERIOSUS; DUCTUS VENOSUS; EXTREMELY LOW BIRTH WEIGHT; FALLOT TETRALOGY; GENE EXPRESSION; GESTATIONAL AGE; HEART; HEART ATRIUM SEPTUM DEFECT; HEART CONTRACTION; HEART DISEASE; HEART RIGHT VENTRICLE OUTFLOW TRACT; HEART SURGERY; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM DEFECT; HEMODYNAMICS; HUMAN; IN VITRO STUDY; LENGTH OF STAY; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; VASCULAR RESISTANCE; VASCULAR TISSUE;

AGE FACTORS; ANIMALS; CARDIOTONIC AGENTS; CHILD; HEART DISEASES; HUMANS; MYOCARDIUM; RECEPTORS, CATECHOLAMINE;

EID: 79960425943     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31822233dd     Document Type: Review

References (118)

1. Rang HP, Dale MM, Ritter JM, et al. Pharmacology. 5th ed. Philadelphia, Churchill Livingstone; 2003:36.
2. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci. 2006;100: 323-337. (Pubitemid 44609527)
3. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev. 2001;53:319-356. (Pubitemid 32476119)
4. Cavallotti C, Mancone M, Bruzzone P, et al. Dopamine receptor subtypes in the native human heart. Heart Vessels. 2010;25:432-437.
5. Tonnarini G, Parlapiano C, Cavallotti D, et al. Dopamine receptor subtypes in the human coronary vessels of healthy subjects. J Recept Signal Transduct Res. 2011;31:33-38.
6. Zeng C, Zhang M, Asico LD, et al. The dopaminergic system in hypertension. Clin Sci (Lond). 2007;112:583-597. (Pubitemid 46849549)
7. Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med. 2001;345:1548-1557. (Pubitemid 33144922)
8. Amenta F, Barili P, Bronzetti E, et al. Localization of dopamine receptor subtypes in systemic arteries. Clin Exp Hypertens. 2000;22:277-288. (Pubitemid 30305951)
9. Vanhoutte PM. Endothelial adrenoceptors. J Cardiovasc Pharmacol. 2001;38:796-808. (Pubitemid 32983286)
10. Queen LR, Ferro A. Beta-adrenergic receptors and nitric oxide generation in the cardiovascular system. Cell Mol Life Sci. 2006;63:1070-1083. (Pubitemid 43800776)
11. Steinberg SF. The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. Circ Res. 1999;85:1101-1111.
12. Price DT, Lefkowitz RJ, Caron MG, et al. Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology. Mol Pharmacol. 1994;45:171-175. (Pubitemid 24063068)
13. Stene-Larsen G, Ask JA, Helle KB, et al. Activation of cardiac beta 2 adrenoceptors in the human heart. Am J Cardiol. 1986;57:F7-F10.
14. Bevan JA. The human adrenergic neurovascular mechanism. Fed Proc. 1985;44:317-320. (Pubitemid 15173208)
15. Duckles SP, Banner Jr W. Changes in vascular smooth muscle reactivity during development. Annu Rev Pharmacol Toxicol. 1984;24:65-83. (Pubitemid 14129530)
16. Rudner XL, Berkowitz DE, Booth JV, et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation. 1999;100:2336-2343.
17. Schutzer WE, Mader SL. Age-related changes in vascular adrenergic signaling: clinical and mechanistic implications. Ageing Res Rev. 2003;2: 169-190. (Pubitemid 37443911)
18. Brodde OE. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991;43:203-242.
19. Stiles GL, Caron MG, Lefkowitz RJ. Beta-adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol Rev. 1984;64:661-743. (Pubitemid 14139089)
20. Nielsen H, Hasenkam JM, Pilegaard HK, et al. Age-dependent changes in alpha-adrenoceptor-mediated contractility of isolated human resistance arteries. Am J Physiol. 1992;263(pt 2):H1190-H1196.
21. Brodde OE, Ponicke K. Age-dependent changes of human cardiac (beta)-adrenoceptors. Pharmacol Toxicol Suppl. 1998;83:35-36. (Pubitemid 28350961)
22. OÃâ,â.,¢Malley K, Docherty JR, Kelly JG. Adrenoceptor status and cardiovascular function in ageing. J Hypertens Suppl. 1988;6:S59-S62. (Pubitemid 19043898)
23. Papp JG. Autonomic responses and neurohumoral control in the human early antenatal heart. Basic Res Cardiol. 1988;83:2-9.
24. Resch BA, Papp JG. Effect of adrenaline, noradrenaline, isoproterenol and tyramine on the isolated surviving human fetal heart. Die Wirkung von Adrenalin, Noradrenalin, Isoproterenol und Tyramin am isolierten uberlebenden Herzen humaner Feten. Zentralbl Gynakol. 1982;104: 1451-1461. (Pubitemid 13243912)
25. Palmer GC, Dail WG Jr. Appearance of hormone-sensitive adenylate cyclase in the developing human heart. Pediatr Res. 1975;9:98-103.
26. Coltart DJ, Meldrum SJ, Royds RB, et al. Study of the contractile and electrophysiological maturation responses of the human foetal myocardium. Br J Pharmacol. 1971;42:P653-P654.
27. Coltart DJ, Spilker BA. Development of human foetal inotropic responses to catecholamines. Experientia. 1972;28:525-526.
28. Coltart DJ, Davies GM, Gillibrand IM, et al. Adenyl cyclase activity in the developing human foetal heart. J Physiol. 1972;225:P38-P40.
29. Chang TD, Cumming GR. Chronotropic responses of human heart tissue cultures. Circ Res. 1972;30:628-633.
30. Gennser G, Rosengren E, von Studnitz W. Distribution of noradrenaline and of monoamine oxidase and catechol-O-methyltransferase activity in human foetal heart. Experientia. 1973;29:20-22.
31. Gennser G, von Studnitz W. Monoamine oxidase, catechol-Omethyltransferase and phenylethanolamine-N-methyltransferase activity in para-aortic tissue of the human fetus. Scand J Clin Lab Invest. 1969; 24:169-171.
32. Dail WG Jr, Palmer GC. Localization and correlation of catecholaminecontaining cells with adenyl cyclase nd phosphodiesterase activities in the human fetal heart. Anat Rec. 1973;177:265-287.
33. Partanen S, Korkala O. Catecholamines in human fetal heart. Experientia. 1974;30:798-800.
34. Walker D. Functional development of the autonomic innervation of the human fetal heart. Biol Neonate. 1974;25:31-43.
35. Saarikoski S. Functional development of adrenergic uptake mechanisms in the human fetal heart. Biol Neonate. 1983;43:158-163. (Pubitemid 13119965)
36. Bkaily G, El-Bizri N, Bui M, et al. Modulation of intracellular Ca2+ via L-type calcium channels in heart cells by the autoantibody directed against the second extracellular loop of the alpha1-adrenoceptors. Can J Physiol Pharmacol. 2003;81:234-246. (Pubitemid 36523647)
37. Aronson S, Gennser G, Owman C, et al. Innervation and contractile response of the human ductus arteriosus. Eur J Pharmacol. 1970;11: 178-186.
38. Boreus LO, Malmfors T, McMurphy DM, et al. Demonstration of adrenergic receptor function and innervation in the ductus arteriosus of the human fetus. Acta Physiol Scand. 1969;77:316-321.
39. Ehinger B, Gennser G, Owman C, et al. Histochemical and pharmacological studies on amine mechanisms in the umbilical cord, umbilical vein and ductus venosus of the human fetus. Acta Physiol Scand. 1968;72:15-24.
40. Sucharov C, Miyamoto S, Nelson P, et al. Regulation of (beta)- adrenergic receptors in pediatric heart failure. Circ Res. 2009;105: e31-e32.
41. Berkenboom G, Fontaine J, Desmet JM, et al. Comparison of the effect of beta adrenergic antagonists with different ancillary properties on isolated canine and human coronary arteries. Cardiovasc Res. 1987;21: 299-304. (Pubitemid 17057822)
42. Berkenboom G, Depierreux M, Fontaine J. The influence of atherosclerosis on the mechanical responses of human isolated coronary arteries to substance P, isoprenaline and noradrenaline. Br J Pharmacol. 1987;92:113-120. (Pubitemid 17134929)
43. Sun LS, Du F, Quaegebeur JM. Right ventricular infundibular betaadrenoceptor complex in tetralogy of Fallot patients. Pediatr Res. 1997; 42:12-16. (Pubitemid 27276752)
44. Brodde OE, Zerkowski HR, Borst HG, et al. Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors. Eur Heart J. 1989;10(suppl B):38-44. (Pubitemid 19182630)
45. Molenaar P, Bartel S, Cochrane A, et al. Both beta(2)- and beta(1)- adrenergic receptors mediate hastened relaxation and phosphorylation of phospholamban and troponin I in ventricular myocardium of Fallot infants, consistent with selective coupling of beta(2)-adrenergic receptors to G(s)-protein. Circulation. 2000;102:1814-1821.
46. Brodde OE, Zerkowski HR, Schranz D, et al. Age-dependent changes in the beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in human right atrium. J Cardiovasc Pharmacol. 1995;26:20-26.
47. Kozlik R, Kramer HH, Wicht H, et al. Myocardial beta-adrenoceptor density and the distribution of beta 1- and beta 2-adrenoceptor subpopulations in children with congenital heart disease. Eur J Pediatr. 1991;150:388-394.
48. Kozlik R, Kramer HH, Wicht H, et al. Beta-adrenoceptor density on mononuclear leukocytes and right atrial myocardium in infants and children with congenital heart disease. Klin Wochenschr. 1991;69: 910-916.
49. Buchhorn R, Hulpke-Wette M, Ruschewski W, et al. Effects of therapeutic beta blockade on myocardial function and cardiac remodelling in congenital cardiac disease. Cardiol Young. 2003;13: 36-43. (Pubitemid 41373802)
50. Buchhorn R, Hulpke-Wette M, Ruschewski W, et al. Beta-receptor downregulation in congenital heart disease: a risk factor for complications after surgical repair? Ann Thorac Surg. 2002;73:610-613. (Pubitemid 34126352)
51. Kozlik-Feldmann R, Kramer HH, Wicht H, et al. Distribution of myocardial beta-adrenoceptor subtypes and coupling to the adenylate cyclase in children with congenital heart disease and implications for treatment. J Clin Pharmacol. 1993;33:588-595. (Pubitemid 23215544)
52. McGrath LB, Chen C, Gu J, et al. Determination of infundibular innervation and amine receptor content in cyanotic and acyanotic myocardium: relation to clinical events in tetralogy of Fallot. Pediatr Cardiol. 1991;12:155-160.
53. Kaumann AJ, Lemoine H, Schwederski-Menke U, et al. Relations between beta-adrenoceptor occupancy and increases of contractile force and adenylate cyclase activity induced by catecholamines in human ventricular myocardium. Acute desensitization and comparison with feline ventricle. Naunyn Schmiedebergs Arch Pharmacol. 1989;339: 99-112. (Pubitemid 19074405)
54. Reithmann C, Reber D, Kozlik-Feldmann R, et al. A post-receptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease. Eur J Pharmacol. 1997;330:79-86. (Pubitemid 27304036)
55. Schranz D, Droege A, Broede A, et al. Uncoupling of human cardiac beta-adrenoceptors during cardiopulmonary bypass with cardioplegic cardiac arrest. Circulation. 1993;87:422-426. (Pubitemid 23040911)
56. Borthne K, Haga P, Langslet A, et al. Functional characterization of an ex vivo preparation of atrial myocardium from children with congenital heart defects: sensitivity to tyramine and adrenoceptor antagonists. J Cardiovasc Pharmacol. 1994;24:365-371. (Pubitemid 24260515)
57. Borthne K, Haga P, Langslet A, et al. Endogenous norepinephrine stimulates both alpha 1- and beta-adrenoceptors in myocardium from children with congenital heart defects. J Mol Cell Cardiol. 1995;27: 693-699.
58. Borthne K, Langslet A, Lindberg H, et al. Differential recruitment of alpha 1- and beta-adrenoceptors in inotropic control of atrial child myocardium by endogenous noradrenaline. Acta Physiol Scand. 2000; 170:21-31.
59. Shavit G, Sagy M, Nadler E, et al. Myocardial response to alpha-agonist (phenylephrine) in relation to age. Crit Care Med. 1989;17:1324-1327. (Pubitemid 20039127)
60. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest. 1983; 72:732-738. (Pubitemid 13051335)
61. Simpson PC, Long CS, Waspe LE, et al. Transcription of early developmental isogenes in cardiac myocyte hypertrophy. J Mol Cell Cardiol. 1989;21(suppl. 5):79-89. (Pubitemid 20047552)
62. Waspe LE, Ordahl CP, Simpson PC. The cardiac beta-myosin heavy chain isogene is induced selectively in alpha 1-adrenergic receptorstimulated hypertrophy of cultured rat heart myocytes. J Clin Invest. 1990;85:1206-1214. (Pubitemid 20123764)
63. Knowlton KU, Michel MC, Itani M, et al. The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem. 1993;268: 15374-15380. (Pubitemid 23222024)
64. Karczewski P, Haase H, Hempel P, et al. Agonistic antibody to the (alpha)1-adrenergic receptor mobilizes intracellular calcium and induces phosphorylation of a cardiac 15-kDa protein. Mol Cell Biochem. 2010; 333:233-242.
65. Deng XF, Sculptoreanu A, Mulay S, et al. Crosstalk between alpha-1A and alpha-1B adrenoceptors in neonatal rat myocardium: implications in cardiac hypertrophy. J Pharmacol Exper Therap. 1998;286:489-496. (Pubitemid 28318025)
66. Autelitano DJ, Woodcock EA. Selective activation of alpha1Aadrenergic receptors in neonatal cardiac myocytes is sufficient to cause hypertrophy and differential regulation of alpha1-adrenergic receptor subtype mRNAs. J Mol Cell Cardiol. 1998;30:1515-1523. (Pubitemid 28418642)
67. Rokosh DG, Stewart AFR, Chang KC, et al. (alpha)1-Adrenergic receptor subtype mRNAs are differentially regulated by (alpha)1- adrenergic and other hypertrophic stimuli in cardiac myocytes in culture and in vivo. Repression of (alpha)(1B) and (alpha)(1D) but induction of (alpha)(1C). J Biol Chem. 1996;271:5839-5843.
68. Filtz TM, Grubb DR, McLeod-Dryden TJ, et al. Gq-initiated cardiomyocyte hypertrophy is mediated by phospholipase Cbeta1b. FASEB J. 2009;23:3564-3570.
69. Lee KH, Lee N, Lim S, et al. Calreticulin inhibits the MEK1,2-ERK1,2 pathway in alpha 1-adrenergic receptor/Gh-stimulated hypertrophy of neonatal rat cardiomyocytes. J Steroid BiochemMol Biol. 2003;84:101-107. (Pubitemid 36324442)
70. Maruyama Y, Nishida M, Sugimoto Y, et al. Galpha(12/13) mediates alpha(1)-adrenergic receptor-induced cardiac hypertrophy. Circ Res. 2002;91:961-969. (Pubitemid 35375250)
71. Wang Y, Su B, Sah VP, et al. Cardiac hypertrophy induced by mitogenactivated protein kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem. 1998;273:5423-5426. (Pubitemid 28124000)
72. Yamazaki T, Komuro I, Zou Y, et al. Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both alpha 1- and beta-adrenoceptors. Circulation. 1997;95:1260-1268. (Pubitemid 27097839)
73. Eskildsen-Helmond YE, Bezstarosti K, Dekkers DH, et al. Cross-talk between receptor-mediated phospholipase C-beta and D via protein kinase C as intracellular signal possibly leading to hypertrophy in serum-free cultured cardiomyocytes. J Mol Cell Cardiol. 1997;29: 2545-2559. (Pubitemid 27404446)
74. Post GR, Goldstein D, Thuerauf DJ, Glembotski CC, et al. Dissociation of p44 and p42 mitogen-activated protein kinase activation from receptor-induced hypertrophy in neonatal rat ventricular myocytes. J Biol Chem. 1996;271:8452-8457. (Pubitemid 26108683)
75. Sah VP, Hoshijima M, Chien KR, et al. Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem. 1996;271:31185-31190. (Pubitemid 26408561)
76. Glennon PE, Kaddoura S, Sale EM, et al. Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ Res. 1996;78:954-961. (Pubitemid 26166703)
77. Hannan RD, Luyken J, Rothblum LI. Regulation of rDNA transcription factors during cardiomyocyte hypertrophy induced by adrenergic agents. J Biol Chem. 1995;270:8290-8297.
78. Thorburn J, Frost JA, Thorburn A. Mitogen-activated protein kinases mediate changes in gene expression, but not cytoskeletal organization associated with cardiac muscle cell hypertrophy. J Cell Biol. 1994;126: 1565-1572. (Pubitemid 24284618)
79. LaMorte VJ, Thorburn J, Absher D, et al. Gq- and ras-dependent pathways mediate hypertrophy of neonatal rat ventricular myocytes following alpha 1-adrenergic stimulation. J Biol Chem. 1994;269: 13490-13496.
80. Simpson P. Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res. 1985;56: 884-894. (Pubitemid 15231512)
81. Morisco C, Zebrowski DC, Vatner DE, et al. (beta)-adrenergic cardiac hypertrophy is mediated primarily by the (beta)1-subtype in the rat heart. J Mol Cell Cardiol. 2001;33:561-573. (Pubitemid 32539011)
82. Germack R, Dickenson JM. Induction of beta3-adrenergic receptor functional expression following chronic stimulation with noradrenaline in neonatal rat cardiomyocytes. J Pharmacol Exp Ther. 2006;316: 392-402. (Pubitemid 41832619)
83. Zeiders JL, Seidler FJ, Iaccarino G, et al. Ontogeny of cardiac betaadrenoceptor desensitization mechanisms: agonist treatment enhances receptor/G-protein transduction rather than eliciting uncoupling. J Mol Cell Cardiol. 1999;31:413-423. (Pubitemid 29089889)
84. Sun LS. Regulation of myocardial beta-adrenergic receptor function in adult and neonatal rabbits. Biol Neonate. 1999;76:181-192. (Pubitemid 29405589)
85. Stein HM, Oyama K, Sapien R, et al. Prolonged beta-agonist infusion does not induce desensitization or down-regulation of beta-adrenergic receptors in newborn sheep. Pediatr Res. 1992;31:462-467.
86. Deng XF, Rokosh DG, Simpson PC. Autonomous and growth factor-induced hypertrophy in cultured neonatal mouse cardiac myocytes: comparison with rat. Circ Res. 2000;87:781-788.
87. Ostrom RS, Violin JD, Coleman S, et al. Selective enhancement of betaadrenergic receptor signaling by overexpression of adenylyl cyclase type 6: colocalization of receptor and adenylyl cyclase in caveolae of cardiac myocytes. Mol Pharmacol. 2000;57:1075-1079. (Pubitemid 30253394)
88. Tepe NM, Liggett SB. Transgenic replacement of type V adenylyl cyclase identifies a critical mechanism of beta-adrenergic receptor dysfunction in the G alpha q overexpressing mouse. FEBS Lett. 1999; 458:236-240. (Pubitemid 29428190)
89. Nunn C, Zou MX, Sobiesiak AJ, et al. RGS2 inhibits beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Cell Signal. 2010;22: 1231-1239.
90. Sobiesiak AJ, Nguyen CH, Chidiac P. Focused Conference Group: P06-the heart gone wrong; stabilization of cardiac function mechanism of the anti-hypertrophic action of RGS2 in cardiomyocytes. Basic Clin Pharmacol Toxicol. 2010;107:586.
91. Song Y, Feng W, Ma X, et al. (beta)-Adrenergic receptor mediates miR- 21 up-regulation in heart by activating STAT3. J Mol Cell Cardiol. 2010; 48:S174.
92. Zhang X, TangM, Gao E, et al. PKA inhibition prevents myocyte death and hypertrophy induced by adrenergic agonists and ameliorates adverse remodeling upon cardiac stress imposition. Circ Res. 2009; 105:e61-e62.
93. Colella M, Pozzan T. Cardiac cell hypertrophy in vitro: role of calcineurin/NFAT as Ca2+ signal integrators. Ann N Y Acad Sci. 2008; 1123:64-68. (Pubitemid 351431304)
94. Zou MX, Roy AA, Zhao Q, et al. RGS2 is upregulated by and attenuates the hypertrophic effect of alpha1-adrenergic activation in cultured ventricular myocytes. Cell Signal. 2006;18:1655-1663.
95. Zolk O, Marx M, Jackel E, et al. (beta)-Adrenergic stimulation induces cardiac ankyrin repeat protein expression: Involvement of protein kinase A and calmodulin-dependent kinase. Cardiovasc Res. 2003;59:563-572. (Pubitemid 38368672)
96. Rau T, Nose M, Remmers U, et al. Overexpression of wild-type Galpha(i)-2 suppresses beta-adrenergic signaling in cardiac myocytes. FASEB jl 2003;17:523-525.
97. Zeiders JL, Seidler FJ, Slotkin TA. Ontogeny of G-protein expression: control by beta-adrenoceptors. Brain Res Dev Brain Res. 2000;120: 125-134. (Pubitemid 30209905)
98. Yonemochi H, Yasunaga S, Teshima Y, et al. Rapid electrical stimulation of contraction reduces the density of beta-adrenergic receptors and responsiveness of cultured neonatal rat cardiomyocytes. Possible involvement of microtubule disassembly secondary to mechanical stress. Circulation. 2000;101:2625-2630. (Pubitemid 30350642)
99. Slotkin TA, Saleh JL, Zhang J, et al. Ontogeny of beta-adrenoceptor/ adenylyl cyclase desensitization mechanisms: the role of neonatal innervation. Brain Res. 1996;742:317-328. (Pubitemid 27016038)
100. Eble DM, Qi M,Waldschmidt S, et al. Contractile activity is required for sarcomeric assembly in phenylephrine-induced cardiac myocyte hypertrophy. Am J Physiol Cell Physiol. 1998;274:C1226-C1237.
101. Zheng L, Wibo M, Kolar F, et al. Calcium channels and cation transport ATPases in cardiac hypertrophy induced by aortic constriction in newborn rats. Mol Cell Biochem. 1996;163-164:23-29. (Pubitemid 26421482)
102. Yamada S, Ohkura T, Yamadera T, et al. Abnormality in plasma catecholamines and myocardial adrenoceptors in cardiomyopathic BIO 53.58 Syrian hamsters and improvement by metoprolol treatment. J Pharmacol Exp Ther. 1997;283:1389-1395. (Pubitemid 28016515)
103. Rossner KL, Coudrai PR. Contractile properties of papillary muscle from young cardiomyopathic hamsters: effects of isoprenaline. Cardiovasc Res. 1986;20:609-613. (Pubitemid 16053585)
104. Staley NA, Noren GR, Einzig S, et al. Effect of early propranolol treatment in an animal model of congestive cardiomyopathy. II. betaadrenergic receptors and left ventricular function. Cardiovasc Res. 1984; 18:561-566. (Pubitemid 14067613)
105. Washington B, Butler K, Doye AA, et al. Heart function challenged with beta-receptor agonism or antagonism in a heart failure model. Cardiovasc Drugs Ther. 2001;15:479-486. (Pubitemid 34163934)
106. Christ T, Wettwer E, Dobrev D, et al. Autoantibodies against the (beta)1- adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol. 2001;33:1515-1525. (Pubitemid 32681669)
107. Bernstein D, Voss E, Huang S, et al. Differential regulation of right and left ventricular (beta)-adrenergic receptors in newborn lambs with experimental cyanotic heart disease. J Clin Invest. 1990;85:68-74. (Pubitemid 20030292)
108. Doshi R, Strandness E, Bernstein D. Regulation of atrial autonomic receptors in experimental cyanotic heart disease. Am J Physiol Heart Circ Physiol. 1991;261:H1135-H1140.
109. Bernstein D, Doshi R, Huang S, et al. Transcriptional regulation of left ventricular beta-adrenergic receptors during chronic hypoxia. Circ Res. 1992;71:1465-1471.
110. Li J, Zhang G, Holtby H, et al. Adverse effects of dopamine on systemic hemodynamic status and oxygen transport in neonates after the Norwood procedure. J Am Coll Cardiol. 2006;48:1859-1864. (Pubitemid 44648610)
111. Bohn DJ, Poirier CS, Edmonds JF, et al. Hemodynamic effects of dobutamine after cardiopulmonary bypass in children. Crit Care Med. 1980;8:367-371.
112. Booker PD, Evans C, Franks R. Comparison of the haemodynamic effects of dopamine and dobutamine in young children undergoing cardiac surgery. Br J Anaesth. 1995;74:419-423.
113. Kwapisz MM, Neuhauser C, Scholz S, et al. Hemodynamic effects of dobutamine and dopexamine after cardiopulmonary bypass in pediatric cardiac surgery. Paediatr Anaesth. 2009;19:862-871.
114. Innes PA, Frazer RS, Booker PD, et al. Comparison of the haemodynamic effects of dobutamine with enoximone after open heart surgery in small children. Br J Anaesth. 1994;72:77-81. (Pubitemid 24023568)
115. Laitinen P, Happonen JM, Sairanen H, et al. Amrinone versus dopamine and nitroglycerin in neonates after arterial switch operation for transposition of the great arteries. J Cardiothorac Vasc Anesth. 1999; 13:186-190. (Pubitemid 29204946)
116. Ricci Z, Stazi GV, Di Chiara L, et al. Fenoldopam in newborn patients undergoing cardiopulmonary bypass: controlled clinical trial. Interact Cardiovasc Thorac Surg. 2008;7:1049-1053.
117. Costello JM, Thiagarajan RR, Dionne RE, et al. Initial experience with fenoldopam after cardiac surgery in neonates with an insufficient response to conventional diuretics. Pediatr Crit Care Med. 2006;7: 28-33.
118. Shekerdemian L. Perioperative manipulation of the circulation in children with congenital heart disease. Heart. 2009;95:1286-1296.